시장보고서
상품코드
1338202

세계의 시신경척수염 스펙트럼 장애 시장(2023-2027년)

Global Neuromyelitis Optica Spectrum Disorder Market 2023-2027

발행일: | 리서치사: TechNavio | 페이지 정보: 영문 138 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

시신경척수염 스펙트럼 장애 시장은 2022-20271년에 1억 7,348만 달러, 예측 기간 중 CAGR은 6.16%로 성장할 것으로 예측됩니다.

이 조사 리포트는 시신경척수염 스펙트럼 장애 시장 전체 분석, 시장 규모·예측, 동향, 시장 촉진요인·촉진요인, 과제, 약 25개 벤더를 다룬 벤더 분석 등을 제공합니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공하고 있습니다. 고령 인구의 증가, 신규 치료제 승인과 강력한 의약품 파이프라인, 시신경척수염 스펙트럼 장애의 이환율 증가가 시장을 촉진하고 있습니다.

향후 수년간 시신경척수염 스펙트럼 장애 시장의 성장을 촉진하는 주요 이유의 하나로 NMOSD 치료의 진보를 들고 있습니다. 또한 헬스케어 지출의 증가 및 전략적 제휴의 증가는 시장의 큰 수요로 연결됩니다.

목차

제1장 주요 요약

  • 시장 개요

제2장 시장 구도

  • 시장 에코시스템

제3장 시장 규모

  • 시장의 정의
  • 시장 부문 분석
  • 시장 규모 2022
  • 시장 전망 2022-2027

제4장 시장 규모 실적

  • 세계의 시신경척수염 스펙트럼 장애 시장 2017-2021
  • 용도별 부문 분석 2017-2021
  • 유형별 부문 분석 2017-2021
  • 지역별 부문 분석 2017-2021
  • 국가별 부문 분석 2017-2021

제5장 Five forces 분석

  • Five Forces 요약
  • 구매자의 교섭력
  • 공급 기업의 교섭력
  • 신규 진출업체의 위협
  • 대체품의 위협
  • 경쟁의 위협
  • 시장 현황

제6장 시장 세분화 : 용도별

  • 시장 부문
  • 비교 : 용도별
  • 병원 : 시장 규모와 예측 2022-2027
  • 전문 클리닉 : 시장 규모와 예측 2022-2027
  • 홈케어 : 시장 규모와 예측 2022-2027
  • 시장 기회 : 용도별

제7장 시장 세분화 : 유형별

  • 시장 부문
  • 비교 : 유형별
  • aquaporin-4 항체 사용 : 시장 규모와 예측 2022-2027
  • aquaporin-4 항체 없음 : 시장 규모와 예측 2022-2027
  • 시장 기회 : 유형별

제8장 고객 상황

  • 고객 상황의 개요

제9장 지역별 상황

  • 지역별 세분화
  • 지역별 비교
  • 북미 : 시장 규모와 예측 2022-2027
  • 유럽 : 시장 규모와 예측 2022-2027
  • 아시아 : 시장 규모와 예측 2022-2027
  • 세계의 기타 지역 : 시장 규모와 예측 2022-2027
  • 미국 : 시장 규모와 예측 2022-2027
  • 영국 : 시장 규모와 예측 2022-2027
  • 중국 : 시장 규모와 예측 2022-2027
  • 캐나다 : 시장 규모와 예측 2022-2027
  • 인도 : 시장 규모와 예측 2022-2027
  • 시장 기회 : 지역 상황별

제10장 촉진요인, 과제 및 동향

  • 시장 촉진요인
  • 시장이 해결해야 할 과제
  • 촉진요인과 과제의 영향
  • 시장 동향

제11장 벤더 구도

  • 개요
  • 벤더 구도
  • 혼란의 상황
  • 업계의 리스크

제12장 벤더 분석

  • 대상 벤더
  • 벤더의 시장 포지셔닝
  • AstraZeneca
  • Biogen Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • HBM Holdings Ltd.
  • Horizon Therapeutics Plc
  • Mitsubishi Chemical Group Corp.
  • Opexa Therapeutics Inc.
  • TG Therapeutics Inc.

제13장 부록

KSA 23.09.11

The neuromyelitis optica spectrum disorder market is forecasted to grow by USD 173.48 mn during 2022-2027, accelerating at a CAGR of 6.16% during the forecast period. The report on the neuromyelitis optica spectrum disorder market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, approval of novel therapeutics and strong drug pipeline, and increasing incidence of neuromyelitis optica spectrum disorder.

Technavio's neuromyelitis optica spectrum disorder market is segmented as below:

By Application

  • Hospitals
  • Specialty clinics
  • Homecare

By Type

  • With aquaporin-4 antibodies
  • Without aquaporin-4 antibodies

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the advances in treatment of NMOSD as one of the prime reasons driving the neuromyelitis optica spectrum disorder market growth during the next few years. Also, growing healthcare expenditure and increase in strategic alliances will lead to sizable demand in the market.

The report on the neuromyelitis optica spectrum disorder market covers the following areas:

  • Neuromyelitis optica spectrum disorder market sizing
  • Neuromyelitis optica spectrum disorder market forecast
  • Neuromyelitis optica spectrum disorder market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neuromyelitis optica spectrum disorder market vendors that include AstraZeneca, Biogen Inc., Chugai Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., HBM Holdings Ltd., Horizon Therapeutics Plc, TG Therapeutics Inc., Mitsubishi Chemical Group Corp., and Opexa Therapeutics Inc.. Also, the neuromyelitis optica spectrum disorder market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Application
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global neuromyelitis optica spectrum disorder market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on global neuromyelitis optica spectrum disorder market 2017 - 2021 ($ million)
  • 4.2 Application Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Application Segment 2017 - 2021 ($ million)
  • 4.3 Type Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Application

  • 6.1 Market segments
  • Exhibit 30: Chart on Application - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Application - Market share 2022-2027 (%)
  • 6.2 Comparison by Application
  • Exhibit 32: Chart on Comparison by Application
  • Exhibit 33: Data Table on Comparison by Application
  • 6.3 Hospitals - Market size and forecast 2022-2027
  • Exhibit 34: Chart on Hospitals - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)
  • 6.4 Speciality clinics - Market size and forecast 2022-2027
  • Exhibit 38: Chart on Speciality clinics - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on Speciality clinics - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on Speciality clinics - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on Speciality clinics - Year-over-year growth 2022-2027 (%)
  • 6.5 Homecare - Market size and forecast 2022-2027
  • Exhibit 42: Chart on Homecare - Market size and forecast 2022-2027 ($ million)
  • Exhibit 43: Data Table on Homecare - Market size and forecast 2022-2027 ($ million)
  • Exhibit 44: Chart on Homecare - Year-over-year growth 2022-2027 (%)
  • Exhibit 45: Data Table on Homecare - Year-over-year growth 2022-2027 (%)
  • 6.6 Market opportunity by Application
  • Exhibit 46: Market opportunity by Application ($ million)
  • Exhibit 47: Data Table on Market opportunity by Application ($ million)

7 Market Segmentation by Type

  • 7.1 Market segments
  • Exhibit 48: Chart on Type - Market share 2022-2027 (%)
  • Exhibit 49: Data Table on Type - Market share 2022-2027 (%)
  • 7.2 Comparison by Type
  • Exhibit 50: Chart on Comparison by Type
  • Exhibit 51: Data Table on Comparison by Type
  • 7.3 With aquaporin-4 antibodies - Market size and forecast 2022-2027
  • Exhibit 52: Chart on With aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 53: Data Table on With aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 54: Chart on With aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
  • Exhibit 55: Data Table on With aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
  • 7.4 Without aquaporin-4 antibodies - Market size and forecast 2022-2027
  • Exhibit 56: Chart on Without aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 57: Data Table on Without aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 58: Chart on Without aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
  • Exhibit 59: Data Table on Without aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
  • 7.5 Market opportunity by Type
  • Exhibit 60: Market opportunity by Type ($ million)
  • Exhibit 61: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 63: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibit 64: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 65: Chart on Geographic comparison
  • Exhibit 66: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 UK - Market size and forecast 2022-2027
  • Exhibit 87: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 88: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 89: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibit 90: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.9 China - Market size and forecast 2022-2027
  • Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)
  • 9.10 Canada - Market size and forecast 2022-2027
  • Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • 9.11 India - Market size and forecast 2022-2027
  • Exhibit 99: Chart on India - Market size and forecast 2022-2027 ($ million)
  • Exhibit 100: Data Table on India - Market size and forecast 2022-2027 ($ million)
  • Exhibit 101: Chart on India - Year-over-year growth 2022-2027 (%)
  • Exhibit 102: Data Table on India - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity By Geographical Landscape
  • Exhibit 103: Market opportunity By Geographical Landscape ($ million)
  • Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 105: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 107: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 108: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 109: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 110: Matrix on vendor position and classification
  • 12.3 AstraZeneca
  • Exhibit 111: AstraZeneca - Overview
  • Exhibit 112: AstraZeneca - Product / Service
  • Exhibit 113: AstraZeneca - Key news
  • Exhibit 114: AstraZeneca - Key offerings
  • 12.4 Biogen Inc.
  • Exhibit 115: Biogen Inc. - Overview
  • Exhibit 116: Biogen Inc. - Product / Service
  • Exhibit 117: Biogen Inc. - Key offerings
  • 12.5 Chugai Pharmaceutical Co. Ltd.
  • Exhibit 118: Chugai Pharmaceutical Co. Ltd. - Overview
  • Exhibit 119: Chugai Pharmaceutical Co. Ltd. - Product / Service
  • Exhibit 120: Chugai Pharmaceutical Co. Ltd. - Key offerings
  • 12.6 F. Hoffmann La Roche Ltd.
  • Exhibit 121: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 122: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 123: F. Hoffmann La Roche Ltd. - Key news
  • Exhibit 124: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 125: F. Hoffmann La Roche Ltd. - Segment focus
  • 12.7 HBM Holdings Ltd.
  • Exhibit 126: HBM Holdings Ltd. - Overview
  • Exhibit 127: HBM Holdings Ltd. - Product / Service
  • Exhibit 128: HBM Holdings Ltd. - Key offerings
  • 12.8 Horizon Therapeutics Plc
  • Exhibit 129: Horizon Therapeutics Plc - Overview
  • Exhibit 130: Horizon Therapeutics Plc - Business segments
  • Exhibit 131: Horizon Therapeutics Plc - Key news
  • Exhibit 132: Horizon Therapeutics Plc - Key offerings
  • Exhibit 133: Horizon Therapeutics Plc - Segment focus
  • 12.9 Mitsubishi Chemical Group Corp.
  • Exhibit 134: Mitsubishi Chemical Group Corp. - Overview
  • Exhibit 135: Mitsubishi Chemical Group Corp. - Business segments
  • Exhibit 136: Mitsubishi Chemical Group Corp. - Key offerings
  • Exhibit 137: Mitsubishi Chemical Group Corp. - Segment focus
  • 12.10 Opexa Therapeutics Inc.
  • Exhibit 138: Opexa Therapeutics Inc. - Overview
  • Exhibit 139: Opexa Therapeutics Inc. - Product / Service
  • Exhibit 140: Opexa Therapeutics Inc. - Key offerings
  • 12.11 TG Therapeutics Inc.
  • Exhibit 141: TG Therapeutics Inc. - Overview
  • Exhibit 142: TG Therapeutics Inc. - Product / Service
  • Exhibit 143: TG Therapeutics Inc. - Key offerings

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 144: Inclusions checklist
  • Exhibit 145: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 146: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 147: Research methodology
  • Exhibit 148: Validation techniques employed for market sizing
  • Exhibit 149: Information sources
  • 13.5 List of abbreviations
  • Exhibit 150: List of abbreviations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제